Sophia Genetics SA Cash Flow Conversion Efficiency
Sophia Genetics SA cash flow conversion efficiency. Based on the latest financial reports, Sophia Genetics SA (SOPH) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.79 Million) by net assets ($60.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sophia Genetics SA (2019–2024)
Cash flow conversion efficiency of Sophia Genetics SA from 2019 to 2024. This chart illustrates how Sophia Genetics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sophia Genetics SA stock price for real-time trading data and today's change.
Sophia Genetics SA Cash Flow Conversion Ratio Explained
Sophia Genetics SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sophia Genetics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sophia Genetics SA ranked by their cash flow conversion efficiency. Also see SOPH company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pinlive Foods Co Ltd
SHE:300892
|
0.009x |
|
Wonderla Holidays Limited
NSE:WONDERLA
|
0.024x |
|
Zhejiang XinNong Chemical Co Ltd Class A
SHE:002942
|
0.045x |
|
A-LIVING SM.CI.SV. H YC 1
F:1V0
|
N/A |
|
CJ Corp 4P Pref
KO:00104K
|
0.102x |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
0.051x |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
-0.027x |
|
Experian PLC
LSE:EXPN
|
0.251x |
Annual Cash Flow Conversion Efficiency for Sophia Genetics SA (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sophia Genetics SA from 2019 to 2024. Review how financially flexible is Sophia Genetics SA to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $96.49 Million | $-42.82 Million | -0.444x | -38.36% |
| 2023-12-31 | $151.44 Million | $-48.58 Million | -0.321x | +8.42% |
| 2022-12-31 | $200.13 Million | $-70.09 Million | -0.350x | -66.48% |
| 2021-12-31 | $275.40 Million | $-57.94 Million | -0.210x | +33.36% |
| 2020-12-31 | $100.51 Million | $-31.73 Million | -0.316x | +77.82% |
| 2019-12-31 | $22.25 Million | $-31.68 Million | -1.424x | -- |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more